CA2464660C - Solution d'inhalation a base d'albuterol, et systeme, kit et methode permettant de soulager les symptomes de l'asthme pediatrique - Google Patents
Solution d'inhalation a base d'albuterol, et systeme, kit et methode permettant de soulager les symptomes de l'asthme pediatrique Download PDFInfo
- Publication number
- CA2464660C CA2464660C CA2464660A CA2464660A CA2464660C CA 2464660 C CA2464660 C CA 2464660C CA 2464660 A CA2464660 A CA 2464660A CA 2464660 A CA2464660 A CA 2464660A CA 2464660 C CA2464660 C CA 2464660C
- Authority
- CA
- Canada
- Prior art keywords
- solution
- inhalation solution
- albuterol
- asthma
- inhalation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 title claims abstract description 139
- 229940041682 inhalant solution Drugs 0.000 title claims abstract description 118
- 238000000034 method Methods 0.000 title claims abstract description 32
- 229960002052 salbutamol Drugs 0.000 title abstract description 116
- 208000024891 symptom Diseases 0.000 title description 25
- 208000029771 childhood onset asthma Diseases 0.000 title description 13
- 208000006673 asthma Diseases 0.000 claims abstract description 73
- 206010006482 Bronchospasm Diseases 0.000 claims abstract description 47
- 208000009079 Bronchial Spasm Diseases 0.000 claims abstract description 42
- 208000014181 Bronchial disease Diseases 0.000 claims abstract description 42
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 17
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 17
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 14
- 239000003755 preservative agent Substances 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 41
- 239000006199 nebulizer Substances 0.000 claims description 39
- 229940057282 albuterol sulfate Drugs 0.000 claims description 31
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 18
- 235000002639 sodium chloride Nutrition 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 206010067484 Adverse reaction Diseases 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 14
- 230000002411 adverse Effects 0.000 claims description 14
- 230000006838 adverse reaction Effects 0.000 claims description 14
- 238000002663 nebulization Methods 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 230000007883 bronchodilation Effects 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- 230000003204 osmotic effect Effects 0.000 claims description 10
- 238000003860 storage Methods 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 206010020751 Hypersensitivity Diseases 0.000 claims description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 8
- 208000030961 allergic reaction Diseases 0.000 claims description 7
- 239000011888 foil Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 208000037874 Asthma exacerbation Diseases 0.000 claims description 6
- 206010008479 Chest Pain Diseases 0.000 claims description 6
- 208000005577 Gastroenteritis Diseases 0.000 claims description 6
- 208000008771 Lymphadenopathy Diseases 0.000 claims description 6
- 206010028813 Nausea Diseases 0.000 claims description 6
- 206010033078 Otitis media Diseases 0.000 claims description 6
- 208000024780 Urticaria Diseases 0.000 claims description 6
- 206010006451 bronchitis Diseases 0.000 claims description 6
- 239000007857 degradation product Substances 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 208000018555 lymphatic system disease Diseases 0.000 claims description 6
- 230000008693 nausea Effects 0.000 claims description 6
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 206010022000 influenza Diseases 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 235000011148 calcium chloride Nutrition 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 239000011592 zinc chloride Substances 0.000 claims description 4
- 235000005074 zinc chloride Nutrition 0.000 claims description 4
- AWYDXHUMBDRXQO-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(methoxymethyl)phenol Chemical compound COCC1=CC(C(O)CNC(C)(C)C)=CC=C1O AWYDXHUMBDRXQO-UHFFFAOYSA-N 0.000 claims description 3
- GELQRPHSNNCPNQ-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-methylphenol Chemical compound CC1=CC(C(O)CNC(C)(C)C)=CC=C1O GELQRPHSNNCPNQ-UHFFFAOYSA-N 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- RKUWGGWMRHKETC-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-chloro-6-(hydroxymethyl)phenol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(O)C(CO)=C1 RKUWGGWMRHKETC-UHFFFAOYSA-N 0.000 claims 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims 2
- 239000013011 aqueous formulation Substances 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 description 35
- 102100028085 Glycylpeptide N-tetradecanoyltransferase 1 Human genes 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 229940068196 placebo Drugs 0.000 description 13
- 239000000902 placebo Substances 0.000 description 13
- 230000002354 daily effect Effects 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000002085 persistent effect Effects 0.000 description 10
- 229940127225 asthma medication Drugs 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 6
- 230000007885 bronchoconstriction Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 229920001684 low density polyethylene Polymers 0.000 description 5
- 239000004702 low-density polyethylene Substances 0.000 description 5
- 229940056215 accuneb Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229960001716 benzalkonium Drugs 0.000 description 4
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 4
- 229940125388 beta agonist Drugs 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000005022 packaging material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 229920001903 high density polyethylene Polymers 0.000 description 3
- 239000004700 high-density polyethylene Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000009613 pulmonary function test Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241001550224 Apha Species 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000036647 Medication errors Diseases 0.000 description 2
- 101150034459 Parpbp gene Proteins 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000012864 cross contamination Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 208000024710 intermittent asthma Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229940124624 oral corticosteroid Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 208000033309 Analgesic asthma syndrome Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710081880 Glycylpeptide N-tetradecanoyltransferase 1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 102100032341 PCNA-interacting partner Human genes 0.000 description 1
- 101710196737 PCNA-interacting partner Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011292 agonist therapy Methods 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000024744 aspirin-induced respiratory disease Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- -1 for example Polymers 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- JHHZQADGLDKIPM-UHFFFAOYSA-N hept-3-en-2-one Chemical compound CCCC=CC(C)=O JHHZQADGLDKIPM-UHFFFAOYSA-N 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125369 inhaled corticosteroids Drugs 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000012633 leachable Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 208000007892 occupational asthma Diseases 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940127558 rescue medication Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229940124631 β2-adrenergic bronchodilator Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Solution d'inhalation à base d'albutérol, et système, kit et méthode permettant de soulager le bronchospasme chez les enfants souffrant d'asthme. Dans un mode de réalisation, la solution selon la présente invention est une dose unitaire stérile, prémélangée et prémesurée d'albutérol pour des patients asthmatiques ayant de 2 à 12 ans. Cette solution peut être exempte de produits chimiques anti-microbiens tels que le chlorure de benzalconium. Dans un autre mode de réalisation, la solution selon la présente invention contient environ 0,63 mg ou environ 1,25 mg d'albutérol.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34820301P | 2001-10-26 | 2001-10-26 | |
| US60/348,203 | 2001-10-26 | ||
| US10/034,829 US6702997B2 (en) | 2001-10-26 | 2001-12-27 | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
| US10/034,829 | 2001-12-27 | ||
| AU32975/02 | 2002-04-05 | ||
| AU32975/02A AU3297502A (en) | 2001-10-26 | 2002-04-05 | An albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
| JP2002-145456 | 2002-04-11 | ||
| JP2002145456A JP2003212764A (ja) | 2001-10-26 | 2002-04-11 | 小児喘息の症状を緩和するためのアルブテロール吸入溶液、システム、キット及び方法 |
| PCT/US2002/033352 WO2003037317A1 (fr) | 2001-10-26 | 2002-10-18 | Solution d'inhalation a base d'albuterol, et systeme, kit et methode permettant de soulager les symptomes de l'asthme pediatrique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2464660A1 CA2464660A1 (fr) | 2003-05-08 |
| CA2464660C true CA2464660C (fr) | 2011-12-20 |
Family
ID=27422969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2464660A Expired - Fee Related CA2464660C (fr) | 2001-10-26 | 2002-10-18 | Solution d'inhalation a base d'albuterol, et systeme, kit et methode permettant de soulager les symptomes de l'asthme pediatrique |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1441709A1 (fr) |
| JP (1) | JP2006513129A (fr) |
| CA (1) | CA2464660C (fr) |
| MX (1) | MXPA04003928A (fr) |
| NZ (1) | NZ550304A (fr) |
| WO (1) | WO2003037317A1 (fr) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62292719A (ja) * | 1986-06-12 | 1987-12-19 | Kaken Pharmaceut Co Ltd | 外用澄明水溶性製剤 |
| GB8825892D0 (en) * | 1988-11-04 | 1988-12-07 | Fisons Plc | Pharmaceutical composition |
| EP0673240B1 (fr) * | 1992-12-09 | 1999-03-24 | Boehringer Ingelheim Pharmaceuticals Inc. | Formulations de solutions medicinales aerosol stabilisees |
| WO1995021820A1 (fr) * | 1994-02-10 | 1995-08-17 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveau derive du carbamate et composition correspondante |
| EP0840733B1 (fr) * | 1995-07-11 | 2001-10-24 | Merck & Co., Inc. | Sel de bisulfate de triazolymethyle-indole ethylamine |
| DE19653969A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole |
| US6126919A (en) * | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| DE69804998T2 (de) * | 1997-10-09 | 2002-12-12 | Schering Corp., Kenilworth | Mometasonfuroat-suspensionen zum zerstäuben |
| US20030183224A1 (en) * | 2000-03-01 | 2003-10-02 | Hailey Mark Andrew | Metered dose inhaler |
| US6451289B2 (en) * | 2000-03-24 | 2002-09-17 | Sepracor Inc. | Albuterol formulations |
-
2002
- 2002-10-18 NZ NZ550304A patent/NZ550304A/en not_active IP Right Cessation
- 2002-10-18 EP EP02784157A patent/EP1441709A1/fr not_active Ceased
- 2002-10-18 CA CA2464660A patent/CA2464660C/fr not_active Expired - Fee Related
- 2002-10-18 MX MXPA04003928A patent/MXPA04003928A/es active IP Right Grant
- 2002-10-18 JP JP2003539661A patent/JP2006513129A/ja active Pending
- 2002-10-18 WO PCT/US2002/033352 patent/WO2003037317A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| NZ550304A (en) | 2008-05-30 |
| EP1441709A1 (fr) | 2004-08-04 |
| CA2464660A1 (fr) | 2003-05-08 |
| MXPA04003928A (es) | 2005-03-31 |
| JP2006513129A (ja) | 2006-04-20 |
| WO2003037317A1 (fr) | 2003-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002347948B2 (en) | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma | |
| CA2464735C (fr) | Solution d'inhalation a base d'albuterol et d'ipratropium, et systeme, kit et methode permettant de soulager les symptomes de la bronchopneumopathie chronique obstructive | |
| US6632842B2 (en) | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
| AU2002347948A1 (en) | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma | |
| US20030191151A1 (en) | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
| AU2016264961B2 (en) | Tiotropium inhalation solution for nebulization | |
| JP6511492B2 (ja) | 女性胃不全麻痺に関係する症状の処置 | |
| US20030203930A1 (en) | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
| US20030140920A1 (en) | Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma | |
| US20050175544A1 (en) | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma | |
| AU2006202584B2 (en) | An albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma | |
| IE890881L (en) | Pharmaceutical Compositions | |
| US20190290633A1 (en) | Tiotropium Inhalation Solution for Nebulization | |
| US8084461B2 (en) | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
| NZ550304A (en) | An antimicrobial preservative-free albuterol inhalation solution for the relief of bronchospasm in children with asthma | |
| AU2002353825B2 (en) | An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
| AU2006202585B2 (en) | An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
| CA3080115A1 (fr) | Solution d'inhalation de tiotropium a nebuliser | |
| KR20200125625A (ko) | 모메타손 및 올로파타딘의 조합을 사용하는 소아 대상체의 알레르기성 비염의 치료 | |
| AU2002353825A1 (en) | An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
| JP2010184937A (ja) | 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、キット、吸入溶液を中に有する１容器を作成する方法、および、吸入溶液を作成する方法 | |
| EA052369B1 (ru) | Интраназальные составы на основе эпинефрина и способы лечения заболевания |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20201019 |